Mario D Cordero
Mario D Cordero is an expert in Biochemistry at Pablo de Olavide University (Spain). Mario D Cordero has authored 126 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 462 (community average: 125). How the SLR is computed.
LeadR Profile
Biochemistry
Subspecialties: Pharmacy - Immunology - Genetics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 126
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| cGAS-deficient mice display premature aging associated with derepression of LINE1 elements and inflammation. PMID 42642519 — cells, aging, phenotype, chromatin, aging, premature | Nat Aging | 2026 | 0 |
| NLRP3 haploinsufficiency unmasks a compensatory NLRP1-NLRP3 interaction that drives accelerated aging in mice. PMID 42361162 — biological science disciplines, aging, inflammasomes, haploinsufficiency, therapeutics | Sci Adv | 2026 | 0 |
| Dexketoprofen enhances NLRP3 activation via ATPase activity after canonical stimuli. PMID 40987978 — nigericin, macrophages, inflammasomes | Inflammopharmacology | 2025 | 0 |
| mTOR Modulates NLRP3 Inflammasome Activation via Nuclear Translocation and STAT1 Inhibition. PMID 40498369 — macrophages, sirolimus, inflammasomes, therapeutics | Eur J Immunol | 2025 | 1 |
| The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice. PMID 39192596 — progeria, safety, pharmaceutical preparations, phenotype, inflammasomes, therapeutics | Aging Cell | 2024 | 2 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map